Zacks: Trillium Therapeutics Inc. (NASDAQ:TRIL) Given Average Recommendation of “Strong Buy” by Analysts
Shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Brokers have set a 12-month consensus price objective of $19.00 for the company and are predicting that the company will post ($0.80) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Trillium Therapeutics an industry rank of 88 out of 265 based on the ratings given to related companies.
TRIL has been the subject of several research analyst reports. Zacks Investment Research raised Trillium Therapeutics from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a research note on Thursday, July 14th. Cowen and Company reaffirmed a “buy” rating on shares of Trillium Therapeutics in a research note on Sunday, June 12th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Trillium Therapeutics in a research note on Monday, June 6th. Ladenburg Thalmann began coverage on Trillium Therapeutics in a research note on Wednesday, August 3rd. They issued a “buy” rating and a $18.00 price objective for the company. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of Trillium Therapeutics in a research note on Monday, August 15th.
Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at 14.81 on Monday. The company’s market cap is $115.73 million. Trillium Therapeutics has a 12 month low of $6.62 and a 12 month high of $16.69. The company’s 50 day moving average is $12.53 and its 200-day moving average is $10.42.
Hedge funds have recently added to or reduced their stakes in the stock. Schonfeld Strategic Advisors LLC purchased a new stake in Trillium Therapeutics during the first quarter worth $100,000. Sabby Management LLC purchased a new stake in Trillium Therapeutics during the first quarter worth $131,000. K2 Principal Fund L.P. purchased a new stake in Trillium Therapeutics during the second quarter worth $131,000. Renaissance Technologies LLC increased its stake in Trillium Therapeutics by 5.7% in the first quarter. Renaissance Technologies LLC now owns 25,478 shares of the company’s stock worth $236,000 after buying an additional 1,380 shares in the last quarter. Finally, New Leaf Venture Partners L.L.C. purchased a new stake in Trillium Therapeutics during the second quarter worth $725,000. 39.34% of the stock is owned by institutional investors and hedge funds.
Trillium Therapeutics Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.